ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 0118 • ACR Convergence 2020

    Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service

    Antonio Naranjo Hernandez1, Amparo Molina2, Cristina Sepúlveda2, Francisco Rubiño3, Adrian Quevedo3 and Soledad Ojeda3, 1Hospital Universitario Dr Negrin, Las Palmas, Canarias, Spain, 2Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Spain, 3Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas

    Background/Purpose: Data on the effectiveness of FLS in the medium and long term are needed. The objetive of this study was to analyze the indicators of…
  • Abstract Number: 0533 • ACR Convergence 2020

    Characterization of Older Male Patients with a Fragility Fracture

    Setareh A Williams1, Shanette G Daigle2, Richard Weiss1, Yamei Wang1, Tarun Arora2 and Jeffrey R Curtis3, 1Radius Health, Inc., Waltham, MA, Waltham, MA, 2University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Osteoporosis is associated with significant burden in terms of adverse patient outcomes, mortality, and cost; and is particularly common in the older Medicare population.…
  • Abstract Number: 1976 • ACR Convergence 2020

    High Disease Activity Is Associated with Incident Osteoporotic Fractures Among Veterans with Rheumatoid Arthritis

    Katherine Wysham1, Ted Mikuls2, Bryant England2, Dolores Shoback3, Patricia Katz4, Jose Garcia1, Brian Sauer5, Beth Wallace6, John Richards7, Paul Monach8, Grant Cannon9 and Joshua Baker10, 1VA Puget Sound/University of Washington, Seattle, WA, 2University of Nebraska Medical Center, Omaha, NE, 3San Francisco VA/University of California, San Francisco, San Francisco, CA, 4University of California, San Francisco, Novato, CA, 5University of Utah, Omaha, NE, 6Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, 7Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 8Brigham and Women's, Boston, 9Salt Lake City VA Medical Center and University of Utah, Salt Lake City, 10University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for osteoporosis and fractures yet the disease specific contributions to osteoporotic fractures (OFX) are not well understood.…
  • Abstract Number: 0101 • ACR Convergence 2020

    Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass

    Michael R McClung1, Michael A Bolognese2, Jacques P Brown3, Jean-Yves Reginster4, Bente Langdahl5, Norma Ruiz-Santiago6, Yifei Shi6, Maria Rojeski6, Jen Timoshanko7, Cesar Libanati7, Helina Kassahun6 and Mary Oates6, 1Oregon Osteoporosis Center, Portland, OR, 2Bethesda Health Research Center, Bethesda, MD, 3Laval University and CHU de Québec (CHUL) Research Centre, Québec City, Canada, 4University of Liège, Liège, Belgium, 5Aarhus University Hospital, Aarhus, Denmark, 6Amgen Inc., Thousand Oaks, CA, 7UCB Pharma, Brussels, Belgium

    Background/Purpose: Romosozumab, an anti-sclerostin antibody that increases bone formation while decreasing bone resorption, reduces fracture risk within 12 months. Here we evaluate the effects of…
  • Abstract Number: 0119 • ACR Convergence 2020

    Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes

    Donna Jose1, Micah Yu2, Karina Torralba3, Christina Downey4, Justin Dunn5 and Vinicius Cabido5, 1Loma Linda University Medical Center, Ontario, CA, 2Loma Linda University Medical Center, Loma Linda, CA, 3Loma Linda University School of Medicine, Redlands, CA, 4Loma Linda University Medical Center, Redlands, CA, 5Loma Linda University Medical Center, Loma Linda

    Background/Purpose: Osteoporosis causes significant morbidity, mortality and healthcare burden. There continues to be a care gap in osteoporosis recognition, treatment and prevention. Several healthcare systems…
  • Abstract Number: 0544 • ACR Convergence 2020

    Risk Factors for Lumbar Vertebral Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip

    Marwan Bukhari1 and Mrinalini Dey2, 1Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom, 2Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: The most common site of osteoporotic fragility fractures is the thoracic spine. However, bone mineral density (BMD) measurements at the hip are used to…
  • Abstract Number: 1977 • ACR Convergence 2020

    Delivering Fracture Prevention Through Telemedicine: A Process Evaluation

    Karla Miller1, Melissa Steffen2, Aaron Seaman2, Zachary Anderson1, Janiel Green1, Shardool Patel1, Shylo Wardyn2 and Samantha Solimeo2, 1Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 2Iowa VA Healthcare System, Iowa City, IA

    Background/Purpose: Guidelines recommend osteoporosis screening using dual-energy X-ray absorptiometry (DXA) in men and women at risk for osteoporosis, but screening remains low, especially in men…
  • Abstract Number: 0102 • ACR Convergence 2020

    Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study

    Diana Camelia Dan1, Youssef Ibrahimy2, Berengere Aubry-Rozier3 and Daniel Aeberli4, 1Lausanne University Hospital, Lausanne, Switzerland, 2University of Lausanne, Lausanne, Switzerland, 3Hôpital orthopédique, Lausanne, Switzerland, 4University Hospital of Bern, Bern, Switzerland

    Background/Purpose: There is much controversy surrounding the loss of bone mass in patients with psoriasis arthritis (PsA). We wanted to evaluate the prevalence of osteoporosis…
  • Abstract Number: 0120 • ACR Convergence 2020

    Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases

    Giovanni Adami1, Angelo Fassio2, Alessandro Giollo2, Luca Idolazzi2, Ombretta Viapiana1, Davide Gatti2 and Maurizio Rossini2, 1University of Verona, Verona, Italy, 2Rheumatology Unit, University of Verona, Verona, Italy

    Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
  • Abstract Number: 0650 • ACR Convergence 2020

    Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout

    Marco Ferrández-Jiménez1, Irene Calabuig2, Maria Luisa Peral2, Miguel Gómez-Garberí1 and Mariano Andrés2, 1Universidad Miguel Hernández de Elche, Alicante, Spain, 2Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain

    Background/Purpose: Osteoporosis causes significant morbidity and mortality through the development of fragility fractures, including vertebral fractures (VF). Patients with gout may show an increased risk…
  • Abstract Number: 0103 • ACR Convergence 2020

    The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative

    Rachel Elam1, Sandeepkumar Gupta2, Omar Tolaymat2, Sowmya Vasan3, Carolyn Crandall4, Jean Wactawski-Wende5, Karen Johnson6 and Laura Carbone2, 1Augusta University, Evans, GA, 2Augusta University, Augusta, GA, 3WHI, Seattle, WA, 4UCLA, Los Angeles, CA, 5University of Buffalo, Buffalo, NY, 6University of Tennessee Health Sciences Center, Memphis, TN

    Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
  • Abstract Number: 0121 • ACR Convergence 2020

    Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women

    Rashmi Dhital1, P. Daniel Nicholas2, Gregory Emkey3 and Anthony Donato2, 1Reading Hospital and Medical Center, West Reading, 2Reading Hospital and Medical Center, West Reading, PA, 3Reading Hospital and Medical Center, Reading, PA

    Background/Purpose: Total joint replacement (TJR) is the standard surgical treatment for end-stage hip and knee osteoarthritis (OA). Patient optimization may limit the need for early…
  • Abstract Number: 0926 • ACR Convergence 2020

    Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort

    Sina Famenini1, Jamie Perin2, Kristin Wipfler3, Kaleb Michaud4 and Zsuzsanna McMahan5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2JHUSPH, Baltimore, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Johns Hopkins University, Baltimore

    Background/Purpose:Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of…
  • Abstract Number: 0104 • ACR Convergence 2020

    Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis

    Attila Hamar1, Anita Pusztai2, Edit Végh1, Ágnes Horváth1, Katalin Gulyás1, Szilvia Szamosi1, Zsófia Pethő1, Nóra Bodnár1, Boglárka Soós1, Monika Czókolyová1, Sándor Szántó1, Gabriella Szűcs1, Harjit Bhattoa1, Gábor Nagy1, Gábor Tajti1, Andrea Domján1, Katalin Hodosi1 and Zoltán Szekanecz1, 1University of Debrecen, Debrecen, Hungary, 2University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary

    Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
  • Abstract Number: 0122 • ACR Convergence 2020

    Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry

    Nitasha Khullar1, Lang Chen2, Jeffrey R Curtis3, Joshua Baker4, Huifeng Yun3, Andreas Reimold5 and Maria (Maio) Danila6, 1University of Alabama Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4University of Pennsylvania, Philadelphia, PA, 5Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 6University of Alabama at Birmingham (UAB), Birmingham, AL

    Background/Purpose: Many effective medications are available for osteoporosis treatment. However how rheumatologists use these therapies is not well understood, particularly in patients with concomitant rheumatologic…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology